TY - JOUR
T1 - Is anti-müllerian hormone associated with fecundability? Findings from the EAGeR trial
AU - Zarek, Shvetha M.
AU - Mitchell, Emily M.
AU - Sjaarda, Lindsey A.
AU - Mumford, Sunni L.
AU - Silver, Robert M.
AU - Stanford, Joseph B.
AU - Galai, Noya
AU - White, Mark V.
AU - Schliep, Karen C.
AU - DeCherney, Alan H.
AU - Schisterman, Enrique F.
N1 - Funding Information:
Address all correspondence and requests for reprints to: Enrique F. Schisterman, PhD, Epidemiology Branch, Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, 6100 Executive Boulevard, 7B03, Rockville, MD 20854. E-mail: schistee@mail.nih.gov. This work was supported by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (Contracts HHSN267200603423, HHSN267200603424, and HHSN267200603426). Disclosure Summary: The authors have nothing to disclose.
Publisher Copyright:
Copyright © 2015 by the Endocrine Society.
PY - 2015/11
Y1 - 2015/11
N2 - Objective: The objective of the study was to evaluate whether anti-Müllerian hormone (AMH) is associated with fecundability among women with proven fecundity and a history of pregnancy loss. Design: This was a prospective cohort study within a multicenter, block-randomized, double-blind, placebo-controlled clinical trial (clinicaltrials.gov, number NCT00467363). Setting: The study was conducted at four US medical centers (2006-2012). Participants: Participating women were aged 18-40 years, with a history of one to two pregnancy losses who were actively attempting pregnancy. Main Outcome Measures: Time to human chorionic gonadotropin detected and clinical pregnancy were assessed using Cox proportional hazard regression models to estimate fecundability odds ratios (fecundability odds ratios with 95% confidence interval [CI]) adjusted for age, race, body mass index, income, low-dose aspirin treatment, parity, number of previous losses, and time since most recent loss. Analyses examined by preconception AMH levels: low (<1.00 ng/mL, n = 124); normal (referent 1.00-3.5 ng/mL, n = 595); and high (>3.5 ng/mL, n = 483). Results: Of the 1202 women with baselineAMHlevels, 82 women with lowAMH(66.1%) achieved an human chorionic gonadotropin detected pregnancy, compared with 383 with normal AMH (65.2%) and 315 with high AMH level (65.2%). Low or high AMH levels relative to normal AMH (referent) were not associated with fecundability (low AMH: fecundability odds ratios 1.13, 95% CI 0.85-1.49; high AMH: FOR 1.04, 95% CI 0.87-1.24). Conclusions: Lower and higher AMH values were not associated with fecundability in unassisted conceptions in a cohort of fecund women with a history of one or two prior losses. Our data do not support routine AMH testing for preconception counseling in young, fecund women.
AB - Objective: The objective of the study was to evaluate whether anti-Müllerian hormone (AMH) is associated with fecundability among women with proven fecundity and a history of pregnancy loss. Design: This was a prospective cohort study within a multicenter, block-randomized, double-blind, placebo-controlled clinical trial (clinicaltrials.gov, number NCT00467363). Setting: The study was conducted at four US medical centers (2006-2012). Participants: Participating women were aged 18-40 years, with a history of one to two pregnancy losses who were actively attempting pregnancy. Main Outcome Measures: Time to human chorionic gonadotropin detected and clinical pregnancy were assessed using Cox proportional hazard regression models to estimate fecundability odds ratios (fecundability odds ratios with 95% confidence interval [CI]) adjusted for age, race, body mass index, income, low-dose aspirin treatment, parity, number of previous losses, and time since most recent loss. Analyses examined by preconception AMH levels: low (<1.00 ng/mL, n = 124); normal (referent 1.00-3.5 ng/mL, n = 595); and high (>3.5 ng/mL, n = 483). Results: Of the 1202 women with baselineAMHlevels, 82 women with lowAMH(66.1%) achieved an human chorionic gonadotropin detected pregnancy, compared with 383 with normal AMH (65.2%) and 315 with high AMH level (65.2%). Low or high AMH levels relative to normal AMH (referent) were not associated with fecundability (low AMH: fecundability odds ratios 1.13, 95% CI 0.85-1.49; high AMH: FOR 1.04, 95% CI 0.87-1.24). Conclusions: Lower and higher AMH values were not associated with fecundability in unassisted conceptions in a cohort of fecund women with a history of one or two prior losses. Our data do not support routine AMH testing for preconception counseling in young, fecund women.
UR - http://www.scopus.com/inward/record.url?scp=84958618287&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84958618287&partnerID=8YFLogxK
U2 - 10.1210/jc.2015-2474
DO - 10.1210/jc.2015-2474
M3 - Article
C2 - 26406293
AN - SCOPUS:84958618287
SN - 0021-972X
VL - 100
SP - 4215
EP - 4221
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 11
ER -